[go: up one dir, main page]

WO2005058298B1 - Analogues de fk228 et methodes de production et d'utilisation desdits analogues - Google Patents

Analogues de fk228 et methodes de production et d'utilisation desdits analogues

Info

Publication number
WO2005058298B1
WO2005058298B1 PCT/US2004/041678 US2004041678W WO2005058298B1 WO 2005058298 B1 WO2005058298 B1 WO 2005058298B1 US 2004041678 W US2004041678 W US 2004041678W WO 2005058298 B1 WO2005058298 B1 WO 2005058298B1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cap structure
group
clai
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/041678
Other languages
English (en)
Other versions
WO2005058298A2 (fr
WO2005058298A3 (fr
Inventor
Scott R Rajski
David A Wassarman
Jose A Restituyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Priority to EP04813928A priority Critical patent/EP1713460A2/fr
Publication of WO2005058298A2 publication Critical patent/WO2005058298A2/fr
Publication of WO2005058298A3 publication Critical patent/WO2005058298A3/fr
Publication of WO2005058298B1 publication Critical patent/WO2005058298B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Analogues de FK228 et méthodes de production et d'utilisation desdits analogues. Ces analogues sont de puissants inhibiteurs de l'histone désacétylase et, dans certains modes de réalisation, sont capables de cibler spécifiquement des cellules et tissus cancéreux. Dans des modes de réalisation préférés, ces analogues sont caractérisés par un motif disulfure cyclique.
PCT/US2004/041678 2003-12-10 2004-12-10 Analogues de fk228 et methodes de production et d'utilisation desdits analogues Ceased WO2005058298A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04813928A EP1713460A2 (fr) 2003-12-10 2004-12-10 Analogues de fk228 et leur utilisation comme inhibiteurs de hdac

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52850103P 2003-12-10 2003-12-10
US60/528,501 2003-12-10

Publications (3)

Publication Number Publication Date
WO2005058298A2 WO2005058298A2 (fr) 2005-06-30
WO2005058298A3 WO2005058298A3 (fr) 2005-11-10
WO2005058298B1 true WO2005058298B1 (fr) 2005-12-08

Family

ID=34699874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041678 Ceased WO2005058298A2 (fr) 2003-12-10 2004-12-10 Analogues de fk228 et methodes de production et d'utilisation desdits analogues

Country Status (2)

Country Link
EP (1) EP1713460A2 (fr)
WO (1) WO2005058298A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (fr) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
CA2586228A1 (fr) * 2004-11-17 2006-05-26 The University Of Chicago Inhibiteurs de l'histone desacetylase et leurs methodes d'utilisation
EP1824831A2 (fr) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
BRPI0720734A2 (pt) 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
US8828924B2 (en) * 2009-05-14 2014-09-09 University Of Maryland, Baltimore Methods of treating a diabetic embryopathy
CN113861267B (zh) * 2021-10-25 2023-06-27 深圳湾实验室坪山生物医药研发转化中心 一种缩酯环肽类化合物lzg-pku-h及其合成方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
ES2321584T3 (es) * 2000-07-17 2009-06-09 Astellas Pharma Inc. Fk228 reducido y su uso.
AR035417A1 (es) * 2001-01-27 2004-05-26 Hoffmann La Roche Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
ATE526029T1 (de) * 2001-08-21 2011-10-15 Astellas Pharma Inc Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
WO2003084611A1 (fr) * 2002-04-05 2003-10-16 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide pour la therapie du cancer du rein

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9518094B2 (en) 2010-07-12 2016-12-13 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9468664B2 (en) 2013-12-27 2016-10-18 Celgene Corporation Romidepsin formulations and uses thereof

Also Published As

Publication number Publication date
EP1713460A2 (fr) 2006-10-25
WO2005058298A2 (fr) 2005-06-30
WO2005058298A3 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
WO2005058298B1 (fr) Analogues de fk228 et methodes de production et d'utilisation desdits analogues
RU2013143306A (ru) Применение производного рапамицина
ES2393112T3 (es) Inhibición del mal olor del sudor
WO2008133273A1 (fr) Composition pharmaceutique pour le traitement de la maladie d'alzheimer
EP2269657A3 (fr) Promédicaments contenant de nouveaux liens bio-clivables
ZA200604744B (en) Endoparasiticidal agents for topical application
BRPI0408251A (pt) compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
EP2266622A3 (fr) Promédicaments contenant de nouveaux liens bio-clivables
WO2003061577A8 (fr) Composes polymeres de polyalkylene et utilisations de ceux-ci
GB0112348D0 (en) Compounds
WO2002089782A3 (fr) Dioxanes et leurs utilisations
SE9903894D0 (sv) Novel compounds
MY120466A (en) Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same.
EP1857442A3 (fr) Nouveaux composés antimycobactériens
RU2009117220A (ru) Антибактериальные и противовирусные пептиды из actinomadura namibiensis
CA2196370A1 (fr) Derives de l'isoprene
ATE345787T1 (de) Verwendung von cyclohexenon derivaten zur herstellung eines medikaments für die behandlung von dysurie
RU2007125659A (ru) Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина
WO2003053337A3 (fr) Compositions therapeutiques
RU2224765C1 (ru) Полипептидное соединение, способы его получения, фармацевтическая композиция и способ профилактики или лечения грибковых заболеваний
US20220168279A1 (en) Methods of treating pain with a thiazoline anti-hyperalgesic
CA2237607A1 (fr) Derives triterpenes possedant une activite immunosuppressive
WO2003064617A2 (fr) Isolats de pestalotiopsis microspora et composes derives de ceux-ci
WO2001064663A2 (fr) Analogues biologiquement actifs de discodermolide
RU2004114262A (ru) Нейротензии активные производные 2,3-диарилпиразолидина

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20050929

WWE Wipo information: entry into national phase

Ref document number: 2004813928

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004813928

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004813928

Country of ref document: EP